Skip to content

The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction

The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02334839
Enrollment
150
Registered
2015-01-08
Start date
2014-09-30
Completion date
2015-09-30
Last updated
2015-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction

Brief summary

Preeclampsia toxemia (PET) is a pregnancy related complication that is usually expressed as new onset hypertension and proteinuria after 20 weeks of gestation. scarce data exists regarding the effectiveness of PAT plethysmography use in women with PET and whether adverse results are found compared to healthy gravidas. Thus, we aimed to assess endothelial function using PAT plethysmography in women with PET and compare their results to both healthy gravidas and those with only gestational hypertension. .

Detailed description

Preeclampsia toxemia (PET) is a pregnancy related complication that is usually expressed as new onset hypertension and proteinuria after 20 weeks of gestation. Although the exact pathophysiology is unclear, it's related to abnormal placentation and subsequent vascular pathology. Endothelial dysfunction was found to play a significant role in the risk of cardiovascular event in general. Moreover, few studies found a relation between endothelial dysfunction and PET. There are several methods for the assessment of endothelial function, with Peripheral Artery Tone (PAT) plethysmography being an emerging non-invasive promising technique. However, scarce data exists regarding the effectiveness of PAT plethysmography use in women with PET and whether adverse results are found compared to healthy gravidas. Thus, we aimed to assess endothelial function using PAT plethysmography in women with PET and compare their results to both healthy gravidas and those with only gestational hypertension.

Interventions

Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Maternal age 18-40 years old 2. 27 and above weeks of gestation 3. Singleton pregnancy 4. Agreed to participate in the study and signed on informed consent form.

Exclusion criteria

1. Known ischemic heart disease or angina pectoris 2. Active smoker 3. Dyslipidemia, chronic hypertension. Renal disease, diabetes mellitus (gestational or pregestational) 4. Active treatment with anti-hypertensive medication, anti-aggregation medication or lipid lowering agents.

Design outcomes

Primary

MeasureTime frameDescription
Reactive Hyperemia Index (RHI)24 monthsThe difference in Reactive Hyperemia Index (RHI) as messureas using the ENDOPAT device between the study groups

Countries

Israel

Contacts

Primary ContactLiran Hiersch
liranh@clalit.org.il+972-3-9377490

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026